MARKET

TTOO

TTOO

T2 Biosystems
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.230
-0.020
-1.60%
After Hours: 1.220 -0.01 -0.81% 19:55 09/21 EDT
OPEN
1.230
PREV CLOSE
1.250
HIGH
1.240
LOW
1.200
VOLUME
2.43M
TURNOVER
--
52 WEEK HIGH
3.150
52 WEEK LOW
0.2350
MARKET CAP
181.98M
P/E (TTM)
-1.3490
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
T2 Biosystems to Participate in Sepsis Alliance Summit
Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virusLEXINGTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced
GlobeNewswire · 5d ago
Is T2 Biosystems (TTOO) Stock Outpacing Its Medical Peers This Year?
Is (TTOO) Outperforming Other Medical Stocks This Year?
Zacks · 09/04 15:30
T2 Biosystems Announces CMS Approval Of New Technology Add-On Payment For The T2Bacteria Panel
Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients LEXINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of
Benzinga · 09/04 11:02
T2 Biosystems Announces CMS Approval of a New Technology Add-On Payment for the T2Bacteria® Panel for a Second Year
Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible PatientsLEXINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the U.S. Centers for Medicare & Medicaid Services
GlobeNewswire · 09/04 11:00
Fulgent Genetics leads healthcare gainers; Akebia Therapeutics and NanoViricides among losers
Gainers: Fulgent Genetics (FLGT) +20%. TRACON Pharmaceuticals (TCON) +17%. Applied Genetic Technologies (AGTC) +12%. CNS Pharmaceuticals (CNSP) +11%. Sutro Biopharma (STRO) +11%.Losers: Akebia Therapeutics (AKBA) -72%. T2 Biosystems (TTOO) -13%.Adaptive Biotechnologies (ADPT) -11%. NanoViricides (NNVC) -11%. Baudax Bio
Seekingalpha · 09/03 15:04
Return On Capital Employed Overview: T2 Biosystems
T2 Biosystems (NASDAQ: TTOO) reported Q2 sales of $2.55 million. Earnings fell to a loss of $8.84 million, resulting in a 34.82% decrease from last quarter. T2 Biosystems collected $2.54 million in revenue during Q1, but reported earnings showed a $13.56 million loss.What Is ROCE? Return on Capital Employed
Benzinga · 09/01 14:10
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 12:35
ZM, WORK among premarket gainers
Eastman Kodak (KODK) +44% on D.E.Shaw stake.Priority Technology Holdings (PRTH) +30% as MRI Software to acquire RentPayment business from Priority Technology.Zoom Video Communications (ZM) +31% on Q2 results.Gogo (GOGO) +26% on sale of commercial
Seekingalpha · 09/01 12:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TTOO stock price target is 2.900 with a high estimate of 4.000 and a low estimate of 1.100.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 22.19M
% Owned: 15.00%
Shares Outstanding: 147.95M
TypeInstitutionsShares
Increased
10
3.71M
New
23
552.35K
Decreased
12
776.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.41%
Healthcare Equipment & Supplies
-1.43%
Key Executives
Non-Executive Chairman
John McDonough
President/Chief Executive Officer/Director
John Sperzel
Chief Financial Officer
John Sprague
Chief Operating Officer
Alec Barclay
Chief Scientific Officer
Thomas Lowery
Vice President/General Counsel
Michael Gibbs
Other
Anthony Pare
Lead Director/Independent Director
John Cumming
Director
Seymour Liebman
Independent Director
Thierry Bernard
Independent Director
David Elsbree
Independent Director
Ninfa Saunders
Independent Director
Robin Toft
Independent Director
Stan Lapidus
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average TTOO stock price target is 2.900 with a high estimate of 4.000 and a low estimate of 1.100.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TTOO
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of T2 Biosystems Inc stock information, including NASDAQ:TTOO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTOO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTOO stock methods without spending real money on the virtual paper trading platform.